EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
Kouji Iida(Shimane University), Kaoru Miyazaki(Yokohama City University)
Cited by 77
Related Papers
KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
|British Journal of Cancer|2008|114